• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cancer Molecular Diagnostics: Suppliers Market Report 2014 - Product Image

Cancer Molecular Diagnostics: Suppliers Market Report 2014

  • Published: February 2014
  • Region: Global
  • 153 Pages
  • BioPharm Reports (VennBio Ltd.)

Cancer diagnostics is one of the most dynamic medical fields, reflecting efforts to translate new advances in cancer into improved tests and treatments. Increasingly, researchers and clinicians pursue common goals towards more personalised therapies, resulting in greater market complexity, new research and clinical needs and changes in laboratory practices. At the same time, end-users seek more powerful tests and instrumentation, as well as greater versatility and flexibility, to meet their increasingly diverse testing needs. This report presents the findings from a new market study of cancer molecular diagnostics and provides valuable commercial insights to suppliers in this field.

This market study was carried out to provide market information to laboratory suppliers in the molecular cancer diagnostics field. Its findings include:

- Market growth, marketing and sales opportunities
- End-user current practices and future plans
- Market developments, growth and shrinkage
- Innovation and new product opportunities

This study was conducted through specialist groups of experienced end-users in the molecular cancer diagnistics field and its findings are therefore READ MORE >

1. Introduction
1.1. Introduction
1.2. Market questions

2. Study Participants
2.1 Introduction
2.2. Global regions
2.3. Country
2.4. Job title
2.5. Experience
2.6. Organisation type
2.7. Field
2.8. Purpose
2.9. Role
2.10. Main activity
2.11. Discussion

3. Cancer Types
3.1. Introduction
3.2. Market Question
3.3. Current cancer types
3.4. Future cancer types
3.5. Discussion

4. Cancer Diagnostic Techniques
4.1. Introduction
4.2. Market question
4.3. Current techniques
4.4. Other current techniques
4.5. Future techniques
4.6. Other future techniques
4.7. Discussion

5. Molecule Types
5.1. Introduction
5.2. Market question
5.3. Current molecules
5.4. Other current molecules
5.5. Future molecules
5.6. Other future molecules
5.7. Discussion

6. Study Samples
6.1 Introduction
6.2. Market question
6.3. Sample types
6.4. Other samples
6.5. Discussion

7. Circulating Tumour Cells
7.1. Introduction
7.2. Market question
7.3. Current studies
7.4. Future studies
7.5. Discussion

8. Cancer Stem Cells
8.1. Introduction
8.2. Market question
8.3. Current studies
8.4. Future studies
8.5. Discussion

9. Molecular Cancer Diagnostic Techniques
9.1. Introduction
9.2. Market question
9.3. Current techniques
9.4. Future techniques
9.5. Discussion

10. Cancers Tested using Molecular Diagnostic Techniques
10.2. Market question
10.3. Current cancers
10.4. Other current cancers
10.5. Future cancers
10.6. Other future cancers
10.7. Discussion

11. Molecular Forms
11.1. Introduction
11.2. Market question
11.3. Current molecular forms
11.4. Other current molecular forms
11.5. Future molecular forms
11.6. Other future molecular forms
11.7. Discussion

12. Cancer Molecular Diagnostics Biomarkers
12.1. Introduction
12.2. Market question
12.3. Current molecular biomarkers
12.4. Other current biomarkers
12.5. Future molecular biomarkers
12.6. Other future molecular biomarkers
12.7. Discussion

13. Clinical Utilities of Cancer Molecular Biomarkers
13.1. Introduction
13.2. Market question
13.3. Clinical utilities
13.4. Other clinical utilities
13.5. Discussion

14. Multiplex Methods
14.1. Introduction
14.2. Market question
14.3. Current methods
14.4. Future methods
14.5. Discussion

15. Molecular Cancer Diagnostics Trends
15.1. Introduction
15.2. Market question
15.3. Current diagnostics trends
15.4. Future diagnostics trends
15.5. Discussion

16. Main Suppliers
16.1. Introduction
16.2. Market question
16.3. Current suppliers
16.4. Other current suppliers
16.5. Future suppliers
16.6. Other future suppliers
16.7. Discussion

17. Advantages and Disadvantages of Molecular Cancer Diagnostics
17.1. Introduction
17.2. Market question
17.3. Advantages
17.4. Disadvantages
17.5. Discussion

18. Future requirements in Cancer Molecular Diagnostics
18.1. Introduction
18.2. Market question
18.3. Requirements
18.4. Discussion

19. Replacement of Non-Molecular Cancer Diagnostics
19.1. Introduction
19.2. Market question
19.3. Replacement
19.4. Discussion

20. Automation in Cancer Molecular Diagnostics
20.1. Introduction
20.2. Market question
20.3. Automation
20.4. Preferred suppliers
20.5 Discussion

21. Most Tested Cancers
21.1. Instruction
21.2. Market question
21.3. Cancers
21.4. Discussion

22. Costs of Molecular Diagnostics
22.1. Introduction
22.2 Market question
22.3. Costs
22.4. Market question
22.5. Budget
22.6. Market question
22.7. Preferred suppliers
22.8. Other suppliers
22.9. Discussion

23. Discussion

Figures

Figure 2.2.1 Global regions of participants in MCD, 2014
Figure 2.3.1 Countries of participants in MCD, 2014
Figure 2.4.1 Job titles of participants in MCD, 2014
Figure 2.5.1 Cancer diagnostics experience of participants in MCD, 2014
Figure 2.6.1 Organisations of participants in MCD, 2014
Figure 2.7.1 Fields of participants in MCD, 2014
Figure 2.8.1 Purpose of cancer diagnostics activities of participants in MCD, 2014
Figure 2.9.1 Role of participants in MCD, 2014
Figure 2.10.1 Main activity of participants in MCD, 2014
Figure 3.3.1 Main cancer types participants work with, relating to their use of cancer diagnostics
Figure 3.4.1 Main cancer types participants anticipate working with in three years from now, relating to cancer diagnostics
Figure 4.3.1 Main cancer diagnostic techniques currently used by participants in MCD 2014
Figure 4.5.1 Main cancer diagnostic techniques participants in MCD 2014 anticipate they will be using in three years from now.
Figure 4.7.1 Cancer diagnostic techniques that are anticipated to increase in the next three years.
Figure 4.7.2 Cancer diagnostic techniques that are anticipated to decrease in the next three years.
Figure 5.3.1 Main molecule types currently tested for in cancer diagnostics, by participants in MCD 2014
Figure 5.5.1 Main molecule types participants in MCD 2014 anticipate testing for in three years from now.
Figure 5.7.1 Molecule types investigated in cancer diagnostics that are anticipated to increase in the next three years.
Figure 5.7.2 Molecule types investigated in cancer diagnostics that are anticipated to decrease in the next three years
Figure 6.3.1 Main sample types tested in cancer diagnostics, by participants in MCD 2014
Figure 7.3.1 The current study of Circulating Tumour Cells (CTCs), by participants in MCD 2014
Figure 7.4.1 The anticipated study of Circulating Tumour Cells (CTCs) by participants in MCD 2014, in three years from now
Figure 8.3.1 The current study of Cancer Stem Cells (CSCs), by participants in MCD 2014
Figure 8.4.1 The anticipated study of Cancer Stem Cells (CSCs), by participants in MCD 2014, in three years from now
Figure 9.3.1 Current molecular cancer diagnostic techniques used by participants in MCD 2014
Figure 9.4.1 Molecular cancer diagnostic techniques that participants in MCD 2014 anticipate using in three years from now
Figure 10.3.1 Main cancers currently tested using molecular diagnostic techniques, indicated by participants in MCD 2014
Figure 10.5.1 Main cancers participants in MCD 2014 anticipate testing with molecular diagnostic in three years from now.
Figure 11.3.1 Current molecular forms investigated in molecular cancer diagnostics, by participants in MCD 2014
Figure 11.5.1 Molecular forms that participants in MCD 2014 anticipate they will be investigating in three years from now
Figure 12.3.1 Biomarkers currently investigated in molecular cancer diagnostics, by participants in MCD 2014
Figure 12.5.1 Cancer molecular disease biomarkers that participants in MCD 2014 anticipate they will be investigating in three years from now
Figure 13.3.1 The clinical utilities of disease biomarkers in molecular cancer diagnostics, reported by participants in MCD 2014
Figure 14.3.1 The current use of multiplex methods in molecular cancer diagnostics, indicated by participants in MCD 2014
Figure 14.4.1 The anticipated use of multiplex methods in molecular cancer diagnostics in three years from now, indicated by participants in MCD 2014
Figure 15.3.1 Current trends in the numbers of molecular cancer diagnostic tests carried out by participants in MCD 2014
Figure 15.4. Future anticipated trends in the numbers of molecular cancer diagnostic tests, reported by participants in MCD 2014
Figure 16.3.1 Current main suppliers of molecular cancer diagnostics, indicated by participants in MCD 2014
Figure 16.5.1 Main suppliers of molecular cancer diagnostics that participants in MCD 2014 anticipate the will be purchasing from in three years from now
Figure 17.3.1 The main advantages of molecular cancer diagnostics, compared to other cancer diagnostics, indicated by participants in MCD 2014
Figure 17.5.1 The main disadvantages of molecular cancer diagnostics, compared to other cancer diagnostics, indicated by participants in MCD 2014
Figure 18.3.1 Future requirements in molecular cancer diagnostics, indicated by participants in MCD 2014
Figure 20.3.1. The percentage of their current molecular cancer diagnostics that are automated, indicated by participants in MCD 2014
Figure 20.4.1 Top five preferred suppliers relating to the automation of molecular cancer diagnostic tests, indicated by participants in MCD 2014
Figure 21.3.1 The most tested cancers in terms of numbers of molecular cancer tests carried out, indicated by participants in MCD 2014
Figure 22.3.1 The cost per molecular diagnostic test for the most tested cancer type, indicated by participants in MCD 2014
Figure 22.5.1 the percentage of their budget for the conduct of their single most important molecular cancer diagnostic test, indicated by participants in MCD 2014
Figure 22.7.1 Preferred suppliers of their single most important molecular cancer diagnostic test, indicated by participants in MCD 2014

Tables

Table 2.2.2 Global regions of participants in MCD, 2014
Table 2.3.1 Countries of participants in MCD, 2014
Table 2.4.1 Job titles of participants in MCD, 2014
Table 2.5.1 Cancer diagnostics experience of participants in MCD, 2014
Table 2.6.1 Organisations of participants in MCD, 2014
Table 2.7.1 Fields of participants in MCD, 2014
Table 2.8.1 Purpose of cancer diagnostics activities of participants in MCD, 2014
Table 2.9.1 Role of participants in MCD, 2014
Table 2.10.1 Main activity of participants in MCD, 2014
Table 3.3.1 Main cancer types participants work with, relating to their use of cancer diagnostics
Table 3.4.1 Main cancer types participants anticipate working with in three years from now, relating to molecular cancer diagnostics
Table 4.3.1 Main cancer diagnostic techniques currently used by participants in MCD 2014
Table 4.51. Main cancer diagnostic techniques participants in MCD 2014 anticipate they will be using in three years from now.
Table 4.7.1. Changes in the use or anticipated use of techniques in cancer diagnostics (current vs. three years from now), indicated by participants in MCD 2014.
Table 5.3.1 Main molecule types currently tested for in cancer diagnostics, by participants in MCD 2014
Table 5.5.1 Main molecule types participants in MCD 2014 anticipate testing for in three years from now
Table 5.7.1. Changes in the current study, or anticipated future study, of molecule classes in cancer diagnostics (current vs. three years from now), indicated by participants in MCD 2014.
Table 6.3.1. Main sample types tested in cancer diagnostics, by participants in MCD 2014
Table 7.3.1 The current study of Circulating Tumour Cells (CTCs), by participants in MCD 2014
Tables 7.4.1 The anticipated study of Circulating Tumour Cells (CTCs) by participants in MCD 2014, in three years from now
Table 8.3.1 The current study of Cancer Stem Cells (CSCs), by participants in MCD 2014
Table 8.4.1 The anticipated study of Cancer Stem Cells (CSCs), by participants in MCD 2014, in three years from now
Table 9.3.1 Current molecular cancer diagnostic techniques used by participants in MCD 2014
Table 9.4.1 Molecular cancer diagnostic techniques that participants in MCD 2014 anticipate using in three years from now
Table 9.5.1 the top ten molecular cancer diagnostic techniques that participants in MCD 2014 anticipate will see increased user in three years from now
Table 9.5.1 the top ten molecular cancer diagnostic techniques that participants in MCD 2014 anticipate will see decreased use in three years from now
Table 9.5.2 A comparison of current vs. future anticipated use of molecular cancer diagnostic techniques, indicated by participants in MCD 2014
Table 10.3.1 Main cancers currently tested using molecular diagnostic techniques, indicated by participants in MCD 2014
Table 10.4.1 Main cancers participants in MCD 2014 anticipate testing with molecular diagnostic in three years from now.
Table 11.3.1 Current molecular forms investigated in molecular cancer diagnostics, by participants in MCD 2014
Table 11.5.1 Molecular forms that participants in MCD 2014 anticipate they will be investigating in three years from now
Table 12.3.1 Biomarkers currently investigated in molecular cancer diagnostics, by participants in MCD 2014
Table 12.5.1 Cancer molecular disease biomarkers that participants in MCD 2014 anticipate they will be investigating in three years from now
Table 12.7.1 Changes in the molecular biomarkers that participants in MCD 2014 Investigate in cancer diagnostics (currently, and in three years from now)
Table 13.3.1 The clinical utilities of disease biomarkers in molecular cancer diagnostics, reported by participants in MCD 2014
Table 14.3.1 The current use of multiplex methods in molecular cancer diagnostics, indicated by participants in MCD 2014
Table 14.4.1 The anticipated use of multiplex methods in molecular cancer diagnostics in three years from now, indicated by participants in MCD 2014
Table 15.3.1 Recent trends in the numbers of molecular cancer diagnostic tests carried out by participants in MCD 2014
Table 15.4. Future anticipated trends in the numbers of molecular cancer diagnostic tests, reported by participants in MCD 2014
Table 16.3.1 Current main suppliers of molecular cancer diagnostics, indicated by participants in MCD 2014
Table 16.5.1 Main suppliers of molecular cancer diagnostics that participants in MCD 2014 anticipate the will be purchasing from in three years from now
Table 16.7.1 Changes in the main suppliers indicated by participants in MCD 2014 (currently, and in three years from now)
Table 17.3.1 The main advantages of molecular cancer diagnostics, compared to other cancer diagnostics, indicated by participants in MCD 2014
Table 17.5.1 The main disadvantages of molecular cancer diagnostics, compared to other cancer diagnostics, indicated by participants in MCD 2014
Table 18.3.1 Future requirements in molecular cancer diagnostics, indicated by participants in MCD 2014
Table 19.3.1 Non-molecular cancer diagnostic techniques that are being replaced by molecular techniques, indicated by participants in MCD 2014
Table 19.3.1 Non-molecular cancer diagnostic techniques that are being replaced by molecular techniques, indicated by participants in MCD 2014
Table 20.3.1. The percentage of their current molecular cancer diagnostics that are automated, indicated by participants in MCD 2014
Table 20.4.1 Preferred suppliers relating to the automation of molecular cancer diagnostic tests, indicated by participants in MCD 2014
Table 21.3.1 The most tested cancers in terms of numbers of molecular cancer tests carried out, indicated by participants in MCD 2014
Table 22.7.1 Preferred suppliers of their single most important molecular cancer diagnostic test, indicated by participants in MCD 2014

Note: Product cover images may vary from those shown

ALSO AVAILABLE

RELATED PRODUCTS

Our Clients

Our clients' logos